NO178699C - Fremgangsmåte for fremstilling av antistoff-heterokonjugater for anvendelse ved regulering av lymfocytt-aktivitet og anvendelse av disse heterokonjugater for aktivering, regulering eller diagnose in vitro - Google Patents

Fremgangsmåte for fremstilling av antistoff-heterokonjugater for anvendelse ved regulering av lymfocytt-aktivitet og anvendelse av disse heterokonjugater for aktivering, regulering eller diagnose in vitro

Info

Publication number
NO178699C
NO178699C NO891375A NO891375A NO178699C NO 178699 C NO178699 C NO 178699C NO 891375 A NO891375 A NO 891375A NO 891375 A NO891375 A NO 891375A NO 178699 C NO178699 C NO 178699C
Authority
NO
Norway
Prior art keywords
heteroconjugates
antibody
regulation
lymphocytes
activation
Prior art date
Application number
NO891375A
Other languages
English (en)
Norwegian (no)
Other versions
NO891375D0 (no
NO178699B (no
NO891375L (no
Inventor
Jeffery A Ledbetter
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NO891375D0 publication Critical patent/NO891375D0/no
Publication of NO891375L publication Critical patent/NO891375L/no
Publication of NO178699B publication Critical patent/NO178699B/no
Publication of NO178699C publication Critical patent/NO178699C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Coating With Molten Metal (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO891375A 1988-04-04 1989-03-31 Fremgangsmåte for fremstilling av antistoff-heterokonjugater for anvendelse ved regulering av lymfocytt-aktivitet og anvendelse av disse heterokonjugater for aktivering, regulering eller diagnose in vitro NO178699C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17682588A 1988-04-04 1988-04-04
US27193488A 1988-11-14 1988-11-14

Publications (4)

Publication Number Publication Date
NO891375D0 NO891375D0 (no) 1989-03-31
NO891375L NO891375L (no) 1989-10-05
NO178699B NO178699B (no) 1996-02-05
NO178699C true NO178699C (no) 1996-05-15

Family

ID=26872636

Family Applications (1)

Application Number Title Priority Date Filing Date
NO891375A NO178699C (no) 1988-04-04 1989-03-31 Fremgangsmåte for fremstilling av antistoff-heterokonjugater for anvendelse ved regulering av lymfocytt-aktivitet og anvendelse av disse heterokonjugater for aktivering, regulering eller diagnose in vitro

Country Status (20)

Country Link
EP (1) EP0336379B1 (xx)
JP (1) JP2613106B2 (xx)
KR (1) KR100205833B1 (xx)
CN (1) CN1058296C (xx)
AT (1) ATE133866T1 (xx)
AU (1) AU629204B2 (xx)
DE (1) DE68925593T2 (xx)
DK (1) DK173382B1 (xx)
ES (1) ES2083960T3 (xx)
FI (1) FI105320B (xx)
GR (1) GR3019224T3 (xx)
HU (1) HU213576B (xx)
IE (1) IE72187B1 (xx)
IL (1) IL89823A (xx)
MY (1) MY106592A (xx)
NO (1) NO178699C (xx)
NZ (1) NZ228560A (xx)
PT (1) PT90195B (xx)
YU (1) YU68589A (xx)
ZA (1) ZA892448B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JPH05268986A (ja) * 1990-03-19 1993-10-19 Bristol Myers Squibb Co モノクローナル抗体及びリンパ球の活性法
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
DE69227623T2 (de) * 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
DE69528894T2 (de) 1994-05-02 2003-03-27 Bernd Groner Bifunktionelles protein, herstellung und verwendung
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
EP0945139A1 (en) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Methods and means for the treatment of immune related diseases such as Graft vs. Host disease
EP1189635A4 (en) * 1999-06-17 2003-04-23 Univ Vermont AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH T-CELLS OR B-CELLS B WHICH HAVE BEEN SENSITIZED TO ANTIGENS-SPECIFIC
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
EP1439857B1 (en) * 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
GB0305702D0 (en) * 2003-03-12 2003-04-16 Univ Birmingham Bispecific antibodies
US20230096030A1 (en) * 2020-02-13 2023-03-30 UCB Biopharma SRL Bispecific antibodies against cd9 and cd7
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
EP0153871A3 (en) * 1984-03-01 1987-07-01 Centocor, Inc. Antibody enhancement of immunogenicity of antigen
EP0179872B1 (en) * 1984-04-23 1991-06-19 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
WO1987006240A1 (en) * 1986-04-14 1987-10-22 The General Hospital Corporation Heterobifunctional antibodies and method of use
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.

Also Published As

Publication number Publication date
FI891528A0 (fi) 1989-03-30
NO891375D0 (no) 1989-03-31
HU213576B (en) 1997-08-28
FI105320B (fi) 2000-07-31
KR890015751A (ko) 1989-11-25
DE68925593T2 (de) 1996-06-13
DK159489A (da) 1989-10-05
JPH01304356A (ja) 1989-12-07
NZ228560A (en) 1991-10-25
CN1058296C (zh) 2000-11-08
DK173382B1 (da) 2000-09-11
HUT51338A (en) 1990-04-28
ES2083960T3 (es) 1996-05-01
FI891528A (fi) 1989-10-05
EP0336379A3 (en) 1990-01-31
IL89823A0 (en) 1989-12-15
YU68589A (en) 1991-10-31
MY106592A (en) 1995-06-30
DK159489D0 (da) 1989-04-03
AU3242389A (en) 1989-10-05
PT90195B (pt) 1994-06-30
IE72187B1 (en) 1997-03-26
EP0336379A2 (en) 1989-10-11
NO178699B (no) 1996-02-05
GR3019224T3 (en) 1996-06-30
IE891054L (en) 1989-10-04
ATE133866T1 (de) 1996-02-15
NO891375L (no) 1989-10-05
CN1036988A (zh) 1989-11-08
DE68925593D1 (de) 1996-03-21
JP2613106B2 (ja) 1997-05-21
PT90195A (pt) 1989-11-10
ZA892448B (en) 1989-12-27
KR100205833B1 (ko) 1999-07-01
EP0336379B1 (en) 1996-02-07
AU629204B2 (en) 1992-10-01
IL89823A (en) 1994-07-31

Similar Documents

Publication Publication Date Title
NO178699C (no) Fremgangsmåte for fremstilling av antistoff-heterokonjugater for anvendelse ved regulering av lymfocytt-aktivitet og anvendelse av disse heterokonjugater for aktivering, regulering eller diagnose in vitro
ATE47155T1 (de) Monoklonaler antikoerper.
GR3020108T3 (en) Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes
DK96689D0 (da) Fremgangsmaade til immunbestemmelse og diagnostisk middel til anvendelse ved fremgangsmaaden
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
BR8003501A (pt) Aperfeicoamento no processo de determinacao de um antigeno, anticorpo ou complexo ou conjugado de antigeno-anticorpo, e um conjunto de reagentes para determinacao de reacao de aglutinacao imunoquimica
EP0363109A3 (en) Determination of a chlamydial or gonococcal antigen using a positively-charged ionically binding support
DE69026875D1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
ATE132267T1 (de) Immuntest unter verwendung von antigenen, produziert in heterologen organismen
ATE27494T1 (de) Diagnostisches testsystem.
PT81050B (pt) Anticorpo monoclonal anti-urocinase e processo para a preparacao de composicoes de materia de teste biologicos que o utilizam
ATE125306T1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
Wekerle FUNCTIONALLY DIFFERENT T LYMPHOCYTE SUBCLASSES SHARE AN IDENTICAL CONSTANT RECEPTOR PART
DE68917732D1 (de) Immuntestverfahren von chondrocalcin.
Borek Immunoenzymatic techniques: edited by S. Avrameas, P. Druet, R. Masseyeff and G. Feldmann. Elsevier, Amsterdam, 1983 (vi+ 398 pp.) Dfl. 210.-/$89.25
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.

Legal Events

Date Code Title Description
MK1K Patent expired